Fig. 5: Oral FABP4 inhibitor BMS increases bone density in OVX mice by inhibiting bone resorption. | Nature Communications

Fig. 5: Oral FABP4 inhibitor BMS increases bone density in OVX mice by inhibiting bone resorption.

From: FABP4 inhibition suppresses bone resorption and protects against postmenopausal osteoporosis in ovariectomized mice

Fig. 5

a Schematic illustration of the animal study groups and experimental procedures. The scissors, ovary and syringe icons are from templates provided by ChemDraw. b–d ELISA detection of serum levels of FABP4 (b) PINP (c) and CTX-1(d) at the endpoint. n = 5 mice per group in (b, d) and 10 mice per group in (c). e Micro-CT scans of the distal femur in each group, with trabecular bone highlighted in blue and the 3D analysis conducted within the defined ROI region. f Coronal micro-CT images of the L4-L5 lumbar vertebrae in each group, with the 3D analysis ROI region highlighted in bright blue. g–i BMD (g) Tb.Th (h) and Tb.N (i) of trabecular bone in the distal femur for each group. j–l BMD (j) Tb.Th (k) and Tb.N (l) in the trabecular bone of the L5 lumbar vertebra. m–n Quantitative TRAP staining results (m) and representative images (n) of demineralized proximal tibia sections in each group. n = 4 mice per group (g–m). Scale bar, 400 μm and 100 μm. All data is presented as mean ± SEM with p values (b–d, g–m). ns no significance. Data was analyzed by one-way ANOVA followed by Tukey’s multiple comparisons test (b–d, g–m). Source data are provided as Source Data file.

Back to article page